Verastem Exercises Early Option To License From GenFleet VS-7375 - Quick Facts

(RTTNews) - Verastem Oncology (VSTM) said it has exercised early the option to license from GenFleet Therapeutics VS-7375, a potential best-in-class oral and selective KRAS G12D inhibitor. Also, the company announced preliminary clinical data from the Phase 1 study being conducted by GenFleet in China. Enrollment in the Phase 1 dose-escalation study in China is ongoing.

Dan Paterson, CEO at Verastem Oncology, said: "Our decision to exercise the option early for VS-7375 was based on the safety, pharmacokinetics and efficacy data to date in the Phase 1 study in China, which are in line with our expectations and, importantly, indicate that patients are generally achieving oral bioavailability with exposures that correlate with strong tumor regressions across KRAS G12D mutant preclinical models. We look forward to building on the work GenFleet has started in China to bring VS-7375 to the clinic in the U.S. in mid-2025."

For More Such Health News, visit rttnews.com.